Profile cover photo
Profile photo
Pyrexar Medical
7 followers -
Making a Difference in Cancer Care
Making a Difference in Cancer Care

7 followers
About
Posts

Post has attachment
We had two visits last week, one friendly and one not so friendly.

The very friendly visitor was from Ames Medical, our newest sales and marketing group in Taiwan. Steven, Johnson, and Andy spent the week with us for sales and technical training on the Pyrexar product line. They have some excellent ideas on how to penetrate the Taiwan market and have put together a well thought out strategic sales plan. Read More>

http://pyrexar.com/taiwan-partners-and-water
Add a comment...

Post has attachment
Salt Lake City, Utah Site Visit from South Korea

Pyrexar welcomed Dr. Joon Kim, Chief of the Medical Clinic at Oasis Medical Care Hospital for a site visit in Salt Lake City, Utah. Dr. Kim specializes in treating cancer with hyperthermia. Accompanying the doctor was Pyrexar's South Korea distributors, Harris Maeng of Hanbeam Technologies and Michael Cha, CEO of Ivy-Lab. The group observed Dr. Hayes perform brachytherapy and hyperthermia on a recurrent ovarian tumor patient at the St. Mark's location of Gamma West Cancer Services. There is a lot of positive and innovative outcomes both in patient recovery and reimbursement which I will discuss in a future post.

Read More>
http://pyrexar.com/south-korea-astro-jca
Add a comment...

Post has attachment
The technology used in capacitive hyperthermia has changed very little since its invention in 1916, and its future is in question. The advent of computerized controls and motorized applicator arm has done little to change the way energy flows between electrodes, nor has it improved treatment outcomes. The replacement of wet cotton rags, for current connection, with a water bolus is probably the only real advancement forward of this aging technology. Issues like the inability to steer or shape the heating zone, the inability to increase focus or accuracy, may never be solved.

Read More>
http://pyrexar.com/is-there-a-future-for-capacitive-hyperthermia
Add a comment...

Post has attachment
We are excited to announce the commissioning of a BSD-2000 3D/MR "Universal" System at Grosshardern University Hospital in Munich Germany.

LMU (Ludwig Maximilians University of Munich in Großhadern) has been a pioneer in cancer treatment with hyperthermia. The hospital has treated over 15,000 patient treatments with hyperthermia, many of them with Soft Tissue Sarcoma tumors. This facility was part of a phase III clinical study which illuminated the long-term survival benefits of adding hyperthermia to chemotherapy. LMU is also at the center of the HEAT (Hyperthermia European Adjuvant Trial) study, a randomized, dual-arm trial for pancreatic cancer using chemotherapy plus hyperthermia.

Read More>
http://pyrexar.com/bsd-2000-3d-mr-system-now-in-service
Add a comment...

Post has attachment
Hyperthermia Takes Center Stage in South Korea

Hyperthermia, well known as a radiosensitizer for cancer treatment, has found its way into South Korea’s leading cancer centers. The country, with a population over 50 million, has the third highest cancer rate among women and ranks 8th in the world overall. In addition to treating cancers of the pelvic region with the Pyrexar BSD-2000 Deep Regional Hyperthermia system, physicians have also found profound value in hyperthermia as a palliative treatment. Prescribing hyperthermia to relieve cancer-related pain and increase patient mobility is being used in convalescent centers throughout the country.

The BSD-2000 units are getting quite a workout in centers throughout South Koreas. Some facilities are reporting 8 to 10 treatments a day, every day, generating an estimated 200 patient treatments a month.

During a recent trip to Asia, Pyrexar CEO, Mark Falkowski met with Hanbeam Technologies president, Brian Bay and his team in Seoul, Korea. Hanbeam is a Pyrexar sales leader and has placed 11 BSD-2000 Deep Regional units in the country in the last 12 months. Currently Hanbeam is waiting regulatory approval from the KFDA to import the BSD-500 Superficial Hyperthermia system into the region.

Hanbeam continues to promote hyperthermia with a major presentation in Seoul this month, inviting well-known hyperthermia expert Dr. Jacoba van der Zee from Erasmus University in The Netherlands. Dr. van der zee has authored many clinical papers and several landmark hyperthermia studies. Her extensive clinical experience in treating a range of cancers using hyperthermia makes her a well-spring of knowledge in a country that is embracing the technology.
Add a comment...

Post has attachment
Saudi Cancer Foundation brings Hyperthermia Awareness to KSA

Pyrexar was invited to present its hyperthermia line to the leading oncologists in the KSA (Kingdom of Saudi Arabia) last week. The meeting was organized by the Saudi Cancer Foundation (SCF) with cooperation from the Al Afandi Medical Group. The SCF was formed to increase cancer awareness and inform the public about the importance of early detection and advancements in cancer treatment.

Even though cancer incidence is lower than world average in Saudi Arabia, colorectal cancer, prostate cancer, non-hodgkins lymphoma and lung cancer ranks highest in incidence for the population of 27 million. The country is looking to improve healthcare outcomes and is exploring the benefits of hyperthermia in the treatment of cancer.

Attending via Skype was Mark Falkowski, CEO of Pyrexar Medical. Mr. Falkowski presented Pyrexar's recent achievements in the advancement of radio frequency delivered hyperthermia. RF phased array hyperthermia is well established in its ability to deliver power both to superficial (surface cancers within 4 cm) and deep regional (any depth in the body), to heat tissue to targeted temperatures of 43˚C. A recent study by the University of Amsterdam, “A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia, (Kok and Crezee, 2017) proved that radiative RF, the method used in Pyrexar Medical's BSD-500, is far superior to systems that use capacitive heating methods (i.e. Oncotherm, Celcius 42).

Also presenting was Dr. Mark Hurwitz of Thomas Jefferson University Hospital. Dr. Hurwitz is a widely recognized leader in the fields of thermal medicine and genitourinary oncology, and previously served as Director of Regional Program Development for the Department of Radiation Oncology at the Dana-Farber/Brigham and Women’s Cancer Center, A long time clinician, researcher and hyperthermia expert, Dr. Hurwitz presented clinical results and discussed hyperthermia’s role in the treatment of cancer. A special thanks to the Al Afandi Medical group, Pyrexar's representative in the region, as well as Mira Sirotic of Alltranix in the organization of the event.

Pyrexar Medical has completed product registration and regulatory requirements with the KSA and is preparing to place hyperthermia systems in the kingdom.
Add a comment...

Post has attachment
Recent visit to China

dalian port cityHealthcare spending in China has been increasing over the past few years and China is now the second largest healthcare market in the world. Pyrexar has been represented in China by our trading partner Orientech Dalian for the last 10 years. Ever since the name and address change from BSD Medical to Pyrexar, we have been working with the Chinese regulatory agencies to re-register the product for export to the country. Bureaucracy can take its toll on market presence, especially in the growing field of hyperthermia.

So we took a trip to China to review our regulatory progress and meet with potential customers for our hyperthermia products. As we have experienced in the past, Orientech is a very generous host, treating us very well on each leg of our journey. After some internal discussions with our distributors, we believe we have a direction to alleviate the regulatory blocks so products will again be available in China.

Orientech invited us to present our hyperthermia line to key prospects in the area. The first stop was the Ansteel Group Hospital, a large facility in the Tiedong District of Anshan in the Liaoning Province. The Ansteel Group facility houses centers for Cancer, Genetic Detection, Immunotherapy, and Radiation Oncology. Our next stop was Dalian Municipal Central Hospital in the Shahekou District of Dalian in the Liaoning Province. Dalian Municipal has received many accolades including “top 20 best service hospitals” and “most reliable hospital in the province”. ansteel immunotherapy

After successfully met presentations, not only were the hospitals very excited and receptive about adding hyperthermia to their cancer treatment services, but preferred the newly updated, top of the line, Image Guided Thermal System, the BSD-2000 3D/MR. According to Mrs. Wang, president of Oreintech, there are more than half a dozen hospitals in region looking at the new MRI based system. Now I feel a bit embarrassed teasing the new product without supporting product information. Our first commercial installation of the newly updated product is being signed off this week in Munich, Germany, and we will bring you more details very soon.
Add a comment...

Post has attachment
Kirloskar Group Brings Hyperthermia Cancer Treatment to India

Pyrexar is proud to welcome Kirloskar Technologies to its distributor network. Kirloskar Technologies, popularly known as KTPL, is part of the 100 year old, multi-billion dollar conglomerate, the Kirloskar Group.

KTPL logo 250pxKirloskar has been a successful healthcare enterprise for more than two decades, offering a multi-disciplinary product portfolio catering to the fields of Cardiac Surgery, Interventional Radiology, Interventional Cardiology, Neurosurgery, Nuclear Medicine, Oncology, Radiography, Vascular Surgery, Minimal Invasive Surgery and Plastic & Reconstructive Surgery.

According to cancerindex.org, more than 1 million people were diagnosed with cancer in India in 2012. Cancer death rates stand at 680,000 each year. The National Cancer Registry puts breast cancer as the most common cancer for women in India, with cervical cancer in second. It is estimated that for every two women newly diagnosed with breast cancer, one dies. Every 8 minutes, a woman dies of cervical cancer. The good news is that hyperthermia is a highly effective adjunct treatment of both breast cancer and cervical cancers.

India represents a significant expansion into Asia for Pyrexar. India accounts for one-sixth of the world population, 10 times greater than the population of the United states. Kirloskar believes that Pyrexar’s hyperthermia line is an excellent companion to their radiotherapy product offering and the therapy will play an important role treatment of cancer in the country. There are some real advocates for hyperthermia in the region. We believe these influencers can help bring awareness and acceptance of the technology to cancers centers throughout India.
Add a comment...

Post has attachment
International Scientific Conference of the Polish Society for Hyperthermic Oncology

We are pleased to invite you to the International Scientific Conference of the Polish Society for Hyperthermic Oncology (PTHO). The theme for this year's congress is "The Place for Hyperthermia in Polish Medicine". Poland has been a long time supporter of hyperthermia. There are currently six Pyrexar BSD-500 Superficial Systems, a BSD-2000 Deep Regional System, and an early model BSD-300 in Poland (We have been there for a long time). [see map]

This year the PTHO invited more than 20 speakers, prominent scientists, experts in hyperthermia, from many different countries. Besides polish speakers, you will have the opportunity to hear the lectures of guests from the USA, Holland, Switzerland, Germany, Russia, and China. The main topic of the Conference will cover hyperthermia trends in the treatment of cancer. The conference goal is to present the standard procedures of combining hyperthermia with radiation therapy, chemotherapy and other systemic treatments. One of the sessions will be dedicated to the biology of fever and to the immunological effects of hyperthermia.

The conference will be held on October 20-21st, 2017 in Piekary Slaskie, Poland at the beautiful, and award winning, Hotel Rezydencja Luxury.

Who should go? If you are a thermal oncologist or someone looking to understand how hyperthermia can be used as part of a comprehensive cancer treatment program, this conference touches on all of the topics. Pyrexar will have on display its new BSD-2000 3D/MR applicator which features live 3D non-invasive temperature mapping utilizing MRI guidance for accurate heat placement. A complete program is available on the PTHO website (www.konferencja2017.ptho.pl/programme)

Representing Pyrexar at the event will be CEO, Mark Falkowski and our local distributor Darius Dros and his team from HT Systems. Conference Admission and Hotel prices are extremely affordable, especially for the caliber of speakers and international contacts you will meet. Register before September 19th and save 25%. Registration and information available on the PTHO website.
Add a comment...

Post has attachment
New Study shows that Radiated Hyperthermia is superior to Capacitive Hyperthermia in the Treatment of Superficial Cancerous Tumors. Clinical data demonstrates that adding superficial hyperthermia treatment to radiation in the treatment of Recurrent Chest Wall Tumors (breast cancer) and malignant melanoma can double* the complete response (tumor eliminated) rate. Add Hyperthermia, Your chances of beating cancer DOUBLES!

The downside, not everyone who claims to offer hyperthermia can deliver this potentially life saving benefit. It essential comes down to two heat delivery methodologies; Capacitive vs Radiated Electromagnetic Fields. In a recent comparison study at the Department of Radiation Oncology at the University of Amsterdam, researchers H.P. Kok and J. Crezee compare hyperthermia systems made by Pyrexar, ALBA, Oncotherm, Celcius 42 and Thermotron. SPOILER ALERT: Pyrexar’s BSD-500 Superficial Hyperthermia system is the only one among the systems tested to earn FDA Approval.
Add a comment...
Wait while more posts are being loaded